ホーム>>Lipids>> Fatty Amides>>Arachidonoyl Ethanolamide Phosphate

Arachidonoyl Ethanolamide Phosphate (Synonyms: AEAP, Anandamide Phosphate)

カタログ番号GC42839

アラキドノイルエタノールアミドは、最初に単離され、同じ受容体(CB1およびCB2)で作用するアゴニストとして特徴付けられた内因性カンナビノイド(CB)です。

Products are for research use only. Not for human use. We do not sell to patients.

Arachidonoyl Ethanolamide Phosphate 化学構造

Cas No.: 183323-26-4

サイズ 価格 在庫数 個数
250μg
$33.00
在庫あり
500μg
$61.00
在庫あり
1mg
$116.00
在庫あり
5mg
$521.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Arachidonoyl ethanolamide was the first endogenous cannabinoid (CB) to be isolated and characterized as an agonist acting on the same receptors (CB1 and CB2) as δ9-THC . Since that time, a number of related endocannabinoids have been isolated, most notably 2-arachidonoyl glycerol . The phosphate ester of AEA, AEA-P, has been tested as a water soluble prodrug version of AEA in the treatment of C6 glioma cells in vivo. Here it acts with essentially the same potency as AEA. However, when tested for inhibition of AEA binding to isolated rat brain CB1 receptors, AEA-P is about 5-fold less potent as an agonist with a Ki of about 200 nM. The phosphate esters of AEA and its analogs are also structural variants of lysophosphatidic acid (LPA). However, the effects of AEA-P on the various LPA receptors have not been tested.

レビュー

Review for Arachidonoyl Ethanolamide Phosphate

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Arachidonoyl Ethanolamide Phosphate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.